Cereno Scientific AB (publ) (FRA:4A1)

Market Cap	195.82M +58.3%
Revenue (ttm)	4.22M -46.2%
Net Income	-10.25M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	838
Open	0.6005
Previous Close	0.6300
Day's Range	0.6005 - 0.6005
52-Week Range	0.4148 - 1.1030
Beta	n/a
RSI	47.46
Earnings Date	Feb 27, 2026

About Cereno Scientific AB

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties. Its drugs portfolio ...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 10
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4A1

Financial Performance

In 2024, Cereno Scientific AB's revenue was 80.90 million, an increase of 64.18% compared to the previous year's 49.28 million. Losses were -99.53 million, 106.9% more than in 2023.

Financial numbers in SEK